{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:25:55Z","timestamp":1757618755336,"version":"3.44.0"},"reference-count":41,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2023,4,3]]},"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1136\/ejhpharm-2022-003594","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T13:20:19Z","timestamp":1682342419000},"page":"409-415","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-interleukin-17 therapies for moderate\/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors"],"prefix":"10.1136","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9835-0081","authenticated-orcid":false,"given":"Estela","family":"Garc\u00eda-Mart\u00edn","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital Universitario Infanta Sof\u00eda, San Sebasti\u00e1n de los Reyes, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RM","family":"Romero-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofelia","family":"Baniandr\u00e9s-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Escudero-Vilaplana","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juana","family":"Bened\u00ed-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Pharmacology, Pharmacognosy and Botany Department, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma Morales","family":"de los R\u00edos Luna","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Herranz-Alonso","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Sanjurjo-S\u00e1ez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"2025090701370146000_31.5.409.1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clinic Rev Allerg Immunol"},{"key":"2025090701370146000_31.5.409.2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.23736\/S0392-0488.18.06202-8","article-title":"Psoriasis and the TNF\/IL23\/IL17 axis","volume":"154","author":"Furue","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"key":"2025090701370146000_31.5.409.3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12751"},{"key":"2025090701370146000_31.5.409.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"2025090701370146000_31.5.409.5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13348"},{"key":"2025090701370146000_31.5.409.6","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jdv.14237","article-title":"Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)","volume":"31","author":"Menter","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090701370146000_31.5.409.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"2025090701370146000_31.5.409.8","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"2025090701370146000_31.5.409.9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3109\/09546634.2015.1088127","article-title":"Efficiency of biological therapies in patients with moderate to severe psoriasis: impact of a pharmacotherapeutic protocol","volume":"27","author":"Romero-Jimenez","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"2025090701370146000_31.5.409.10","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.adengl.2018.03.021","article-title":"Absolute versus relative psoriasis area and severity index in clinical practice","volume":"110","author":"del Alc\u00e1zar Viladomiu","year":"2019","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"2025090701370146000_31.5.409.11","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090701370146000_31.5.409.12","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaad.2019.12.038","article-title":"Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis","volume":"82","author":"Warren","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"2025090701370146000_31.5.409.13","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2546161","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"key":"2025090701370146000_31.5.409.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220868","article-title":"Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response","volume":"14","author":"Sawyer","year":"2019","journal-title":"PLoS One"},{"key":"2025090701370146000_31.5.409.15","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1422591"},{"key":"2025090701370146000_31.5.409.16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjd.19325","article-title":"Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta\u2010analysis","volume":"183","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025090701370146000_31.5.409.17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14712598.2018.1481503","article-title":"Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation","volume":"18","author":"Galluzzo","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2025090701370146000_31.5.409.18","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/09546634.2019.1671577","article-title":"Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study","volume":"31","author":"Chiricozzi","year":"2020","journal-title":"Journal of Dermatological Treatment"},{"key":"2025090701370146000_31.5.409.19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/09546634.2018.1528000","article-title":"Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain","volume":"30","author":"Notario","year":"2019","journal-title":"Journal of Dermatological Treatment"},{"key":"2025090701370146000_31.5.409.20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14712598.2020.1708897","article-title":"In which patients the best efficacy of secukinumab? update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis","volume":"20","author":"Galluzzo","year":"2020","journal-title":"Expert Opinion on Biological Therapy"},{"key":"2025090701370146000_31.5.409.21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaad.2019.02.062","article-title":"A prospective multicenter study assessing effectiveness and safety of secukinumab in A real-life setting in 158 patients","volume":"81","author":"Ortiz-Salvador","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025090701370146000_31.5.409.22","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/jcph.876","article-title":"Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis","volume":"57","author":"Bruin","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2025090701370146000_31.5.409.23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/jcm8060770","article-title":"Use of secukinumab in a cohort of erythrodermic psoriatic patients: a pilot study","volume":"8","author":"Damiani","year":"2019","journal-title":"JCM"},{"key":"2025090701370146000_31.5.409.24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/09546634.2018.1473838","article-title":"Drug survival of secukinumab for psoriasis in a real-world setting","volume":"30","author":"Lee","year":"2019","journal-title":"Journal of Dermatological Treatment"},{"key":"2025090701370146000_31.5.409.25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2019.02.031","article-title":"Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study","volume":"81","author":"Torres","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"2025090701370146000_31.5.409.26","doi-asserted-by":"crossref","unstructured":"Sherman S , Zloczower O , Noyman Y , et al . n.d. Ixekizumab survival in heavily pretreated patients with psoriasis: a two-year single-centre retrospective study. Acta Derm Venereol;100:adv00349. doi:10.2340\/00015555-3714","DOI":"10.2340\/00015555-3714"},{"key":"2025090701370146000_31.5.409.27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1203475418814229","article-title":"Ixekizumab (interleukin 17A antagonist): 12-week efficacy and safety outcomes in real-world clinical practice","volume":"23","author":"Georgakopoulos","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"2025090701370146000_31.5.409.28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/jdv.15288","article-title":"Initial results of ixekizumab efficacy and safety in real\u2010world plaque psoriasis patients: a multicentre retrospective study","volume":"33","author":"Deza","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090701370146000_31.5.409.29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/14712598.2021.1849133","article-title":"Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice","volume":"21","author":"Caldarola","year":"2021","journal-title":"Expert Opinion on Biological Therapy"},{"key":"2025090701370146000_31.5.409.30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaad.2019.03.048","article-title":"Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis","volume":"81","author":"Egeberg","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"2025090701370146000_31.5.409.31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/ijd.14429","article-title":"Drug survival of biological therapy is showing class effect: updated results from Slovenian national Registry of psoriasis","volume":"58","author":"Lunder","year":"2019","journal-title":"Int J Dermatol"},{"key":"2025090701370146000_31.5.409.32","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/CCID.S211938","article-title":"Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review","volume":"12","author":"Pinter","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025090701370146000_31.5.409.33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/jdv.16931","article-title":"Brodalumab for the treatment of moderate\u2010to\u2010severe plaque\u2010type psoriasis: a real\u2010life, retrospective 24\u2010week experience","volume":"35","author":"Fargnoli","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090701370146000_31.5.409.34","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jaad.2019.05.007","article-title":"Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17a therapies have failed","volume":"81","author":"Kimmel","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025090701370146000_31.5.409.35","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1080\/09546634.2020.1716932","article-title":"Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker-a retrospective multicenter study","volume":"32","author":"Kromer","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2025090701370146000_31.5.409.36","first-page":"175","article-title":"Efficacy of secukinumab without the initial Weekly loading dose in patients with chronic plaque psoriasis","volume":"182","author":"Gisondi","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025090701370146000_31.5.409.37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150 Mg with or without loading regimen in psoriatic arthritis: results from the future 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025090701370146000_31.5.409.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"2025090701370146000_31.5.409.39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/jdv.15921","article-title":"Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from uncover-3 study","volume":"34","author":"Lebwohl","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090701370146000_31.5.409.40","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bjd.16426","article-title":"Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025090701370146000_31.5.409.41","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1080\/13696998.2021.1970953","article-title":"Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain","volume":"24","author":"Egeberg","year":"2021","journal-title":"J Med Econ"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2022-003594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:37:13Z","timestamp":1757234233000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2022-003594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,8,22]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/ejhpharm-2022-003594"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2022-003594","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"type":"print","value":"2047-9956"},{"type":"electronic","value":"2047-9964"}],"subject":[],"published":{"date-parts":[[2023,4,24]]}}}